Skip to main content
Top
Published in: Health Care Analysis 2/2008

Open Access 01-06-2008 | Original Article

Participatory Workshops are Not Enough to Prevent Policy Implementation Failures: An Example of a Policy Development Process Concerning the Drug Interferon-beta for Multiple Sclerosis

Authors: Margriet Moret-Hartman, Rob Reuzel, John Grin, Gert Jan van der Wilt

Published in: Health Care Analysis | Issue 2/2008

Login to get access

Abstract

A possible explanation for policy implementation failure is that the views of the policy’s target groups are insufficiently taken into account during policy development. It has been argued that involving these groups in an interactive process of policy development could improve this. We analysed a project in which several target populations participated in workshops aimed to optimise the utilisation of an expensive novel drug (interferon beta) for patients with Multiple Sclerosis. All participants seemed to agree on the appropriateness of establishing a central registry of Multiple Sclerosis patients and developing guidelines. Nevertheless, these policy measures were not implemented. Possible explanations include (1) the subject no longer had high priority when the costs appeared lower than expected, (2) the organisers had paid insufficient attention to the perceived problems of parties involved, and (3) changes within the socio-political context. The workshops in which representatives of the policy’s target populations participated did not provide enough interactivity to prevent policy implementation failure.
Literature
1.
go back to reference Behan, P. O., Chaudhuri, A., & Roep, B. O. (2002). Pathogenesis of multiple sclerosis revisited. Journal of the Royal College of Physicians of Edinburgh, 32, 244-265. Behan, P. O., Chaudhuri, A., & Roep, B. O. (2002). Pathogenesis of multiple sclerosis revisited. Journal of the Royal College of Physicians of Edinburgh, 32, 244-265.
2.
go back to reference B&A. (2000). Gebruik van interferon-beta bij multipele sclerose. Den Haag: B&A groep. B&A. (2000). Gebruik van interferon-beta bij multipele sclerose. Den Haag: B&A groep.
3.
go back to reference Coolen, R. (1997). Patientenvoorlichting interferon beta 1b beinvloedt keuzeproces. Pharmaceutisch Weekblad, 132, 1394-1396. Coolen, R. (1997). Patientenvoorlichting interferon beta 1b beinvloedt keuzeproces. Pharmaceutisch Weekblad, 132, 1394-1396.
4.
go back to reference CVZ. (2000a). Onderzoek handelswijze ziekenfondsen bij aanvragen interferon beta bij multipele sclerose. Amstelveen: College voor zorgverzekeringen. CVZ. (2000a). Onderzoek handelswijze ziekenfondsen bij aanvragen interferon beta bij multipele sclerose. Amstelveen: College voor zorgverzekeringen.
5.
go back to reference CVZ. (2000b). Evaluatie van het gebruik van interferon-beta bij multipele sclerose. Amstelveen: College voor zorgverzekeringen. CVZ. (2000b). Evaluatie van het gebruik van interferon-beta bij multipele sclerose. Amstelveen: College voor zorgverzekeringen.
6.
go back to reference Dunn, W. (2004). Public policy analysis. An introduction (3rd ed.). Upper Saddle River, NJ: Pearson/Prentice Hall. Dunn, W. (2004). Public policy analysis. An introduction (3rd ed.). Upper Saddle River, NJ: Pearson/Prentice Hall.
7.
go back to reference Fischer, F. (1999). Evaluating public policy. Chicago, USA: Nelson-Hall Publishers. Fischer, F. (1999). Evaluating public policy. Chicago, USA: Nelson-Hall Publishers.
8.
go back to reference Fischer, F., & Forester, J. (1993). The argumentative turn in policy analysis and planning. Durham, NL: Duke University Press. Fischer, F., & Forester, J. (1993). The argumentative turn in policy analysis and planning. Durham, NL: Duke University Press.
9.
go back to reference Gezondheidsraad. (1996). Toepassing van interferon-beta-1b bij patiënten met multiple sclerose. Den Haag: Gezondheidsraad. Publicatie 1996/05. Gezondheidsraad. (1996). Toepassing van interferon-beta-1b bij patiënten met multiple sclerose. Den Haag: Gezondheidsraad. Publicatie 1996/05.
10.
go back to reference Grin, J., & van de Graaf, H. (1996). Implementation as communicative action. Policy Sciences, 29, 291-319.CrossRef Grin, J., & van de Graaf, H. (1996). Implementation as communicative action. Policy Sciences, 29, 291-319.CrossRef
11.
go back to reference Grin, J., van de Graaf, H., & Hoppe, R. (1997). Interactieve technology assessment. Een eerste gids voor wie het wagen wil. Den Haag: Rathenau Instituut; W57. Grin, J., van de Graaf, H., & Hoppe, R. (1997). Interactieve technology assessment. Een eerste gids voor wie het wagen wil. Den Haag: Rathenau Instituut; W57.
12.
go back to reference Guba, E. G., & Lincoln, Y. S. (1989). Fourth generation evaluation. Newbury Park: Sage Publications. Guba, E. G., & Lincoln, Y. S. (1989). Fourth generation evaluation. Newbury Park: Sage Publications.
13.
go back to reference de Haan, R. J., & Vermeulen, M. (1999). Interferon beta-Ib nu ook voor de secundair progressieve vorm van multiple sclerose? Nederlands Tijdschrift voor Geneeskunde, 143(14), 709-711.PubMed de Haan, R. J., & Vermeulen, M. (1999). Interferon beta-Ib nu ook voor de secundair progressieve vorm van multiple sclerose? Nederlands Tijdschrift voor Geneeskunde, 143(14), 709-711.PubMed
14.
go back to reference Hisschemöller, M. (1993). De democratie van problemen. De relatie tussen de inhoud van beleidsproblemen en methoden van politieke besluitvorming. Amsterdam: VU Uitgeverij. Hisschemöller, M. (1993). De democratie van problemen. De relatie tussen de inhoud van beleidsproblemen en methoden van politieke besluitvorming. Amsterdam: VU Uitgeverij.
15.
go back to reference Hoppe, R., & Peterse, A. (1998). Bouwstenen voor een argumentatieve beleidsanalyse. Den Haag: VUGA. Hoppe, R., & Peterse, A. (1998). Bouwstenen voor een argumentatieve beleidsanalyse. Den Haag: VUGA.
16.
go back to reference IFN MS Group. (1993). Interferon beta-1b is effective in relapsing remitting multiple sclerosis. Clinical results of a multicenter, randomized double-blind, placebo-controlled trial. Neurology, 43, 655-661. IFN MS Group. (1993). Interferon beta-1b is effective in relapsing remitting multiple sclerosis. Clinical results of a multicenter, randomized double-blind, placebo-controlled trial. Neurology, 43, 655-661.
17.
go back to reference Lie, R. K. (2004). Research ethics and evidence based medicine. Journal of Medical Ethics, 30, 122-125.PubMedCrossRef Lie, R. K. (2004). Research ethics and evidence based medicine. Journal of Medical Ethics, 30, 122-125.PubMedCrossRef
18.
go back to reference Moret, M., Reuzel, R. P. B., van der Wilt, G. J., & Grin, J. (2007). Validity and reliability of qualitative data-analysis: Reconstructing interpretative frames. Field Methods, 19, 24–39.CrossRef Moret, M., Reuzel, R. P. B., van der Wilt, G. J., & Grin, J. (2007). Validity and reliability of qualitative data-analysis: Reconstructing interpretative frames. Field Methods, 19, 24–39.CrossRef
19.
go back to reference Netherlands Court of Audit. (1992). Cost containing medicines. 22920, no 2 (in Dutch). Netherlands Court of Audit. (1992). Cost containing medicines. 22920, no 2 (in Dutch).
20.
go back to reference Netherlands Court of Audit. (2003). Between policy and implementation. 28831, no 1-2 (in Dutch). Netherlands Court of Audit. (2003). Between policy and implementation. 28831, no 1-2 (in Dutch).
21.
go back to reference Pieters, T. (1998). Marketing medicines through randomised controlled trials: The case of interferon. BMJ, 317(7167), 1231-1233.PubMed Pieters, T. (1998). Marketing medicines through randomised controlled trials: The case of interferon. BMJ, 317(7167), 1231-1233.PubMed
22.
go back to reference Polman, C. H. (1999). Interferon beta-1b nu ook voor de secundair progressieve vorm van multiple sclerosis? Nederlands Tijdschrift voor Geneeskunde, 143, 815-817.PubMed Polman, C. H. (1999). Interferon beta-1b nu ook voor de secundair progressieve vorm van multiple sclerosis? Nederlands Tijdschrift voor Geneeskunde, 143, 815-817.PubMed
23.
go back to reference PRIMS. (1998). Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet, 352, 1498-1504.CrossRef PRIMS. (1998). Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet, 352, 1498-1504.CrossRef
24.
go back to reference Reuzel, R. P. B. (2001). Health technology assessment and interactive evaluation: Different perspectives. Enschede: PrintPartners Ipskamp. Reuzel, R. P. B. (2001). Health technology assessment and interactive evaluation: Different perspectives. Enschede: PrintPartners Ipskamp.
25.
go back to reference Reuzel, R. (2004). Interactive technology assessment of paediatric cochlear implantation. Poiesis & Praxis, 2, 119-137. Reuzel, R. (2004). Interactive technology assessment of paediatric cochlear implantation. Poiesis & Praxis, 2, 119-137.
26.
go back to reference Rice, G. PA., Incorvaia, B., Munari, L., Ebers, G., Polman, C., D'Amico, R., & Filippini, G. (2002). Interferon-beta in relapsing-remitting multiple sclerosis (Cochrane review). In: The cochrane library, issue 1. Oxford: update software. Rice, G. PA., Incorvaia, B., Munari, L., Ebers, G., Polman, C., D'Amico, R., & Filippini, G. (2002). Interferon-beta in relapsing-remitting multiple sclerosis (Cochrane review). In: The cochrane library, issue 1. Oxford: update software.
27.
go back to reference Schön, D. A. (1983). The reflective practitioner. How professionals think in action. New York, USA: Basic Books. Schön, D. A. (1983). The reflective practitioner. How professionals think in action. New York, USA: Basic Books.
28.
go back to reference Vermeulen, M., & de Haan, R. J. (1999). Nieuwe therapieen in de neurologie, maar wie wordt er beter van? Nederlands Tijdschrift voor Geneeskunde, 143(35), 1764-1766.PubMed Vermeulen, M., & de Haan, R. J. (1999). Nieuwe therapieen in de neurologie, maar wie wordt er beter van? Nederlands Tijdschrift voor Geneeskunde, 143(35), 1764-1766.PubMed
29.
go back to reference Yanow, D. (2000). Conducting interpretative policy analysis. Thousand Oaks: Sage. Yanow, D. (2000). Conducting interpretative policy analysis. Thousand Oaks: Sage.
30.
go back to reference Ziekenfondsraad. (1996). Vervolg-rapport aanspraak interferon-beta-1b. nr.717. Amstelveen: Ziekenfondsraad. Ziekenfondsraad. (1996). Vervolg-rapport aanspraak interferon-beta-1b. nr.717. Amstelveen: Ziekenfondsraad.
Metadata
Title
Participatory Workshops are Not Enough to Prevent Policy Implementation Failures: An Example of a Policy Development Process Concerning the Drug Interferon-beta for Multiple Sclerosis
Authors
Margriet Moret-Hartman
Rob Reuzel
John Grin
Gert Jan van der Wilt
Publication date
01-06-2008
Publisher
Springer US
Published in
Health Care Analysis / Issue 2/2008
Print ISSN: 1065-3058
Electronic ISSN: 1573-3394
DOI
https://doi.org/10.1007/s10728-007-0069-1

Other articles of this Issue 2/2008

Health Care Analysis 2/2008 Go to the issue

Original Article

Well-Being and Health